BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 29369969)

  • 1. The Long Journey of mTOR Inhibitors and the Long Path That Is Still Ahead.
    Tedesco Silva H
    Transplantation; 2018 Feb; 102(2S Suppl 1):S1-S2. PubMed ID: 29369969
    [No Abstract]   [Full Text] [Related]  

  • 2. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 3. mTOR Inhibition and Clinical Transplantation: Heart.
    Zuckermann A; Osorio-Jaramillo E; Aliabadi-Zuckermann AZ
    Transplantation; 2018 Feb; 102(2S Suppl 1):S27-S29. PubMed ID: 29369971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mTOR Inhibition and Clinical Transplantation: Pancreas and Islet.
    Berney T; Andres A; Toso C; Majno P; Squifflet JP
    Transplantation; 2018 Feb; 102(2S Suppl 1):S30-S31. PubMed ID: 28230643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR Inhibition and Kidney Diseases.
    Ma MKM; Yung S; Chan TM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transplantation: time to rethink immunosuppression by mTOR inhibitors?
    Säemann MD; Remuzzi G
    Nat Rev Nephrol; 2009 Nov; 5(11):611-2. PubMed ID: 19855420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mTOR-I on fertility and pregnancy: state of the art and review of the literature.
    Framarino-dei-Malatesta M; Derme M; Manzia TM; Iaria G; De Luca L; Fazzolari L; Napoli A; Berloco P; Patel T; Orlando G; Tisone G
    Expert Rev Clin Immunol; 2013 Aug; 9(8):781-9. PubMed ID: 23971756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. mTOR Inhibition and Cardiovascular Diseases: Cardiac Hypertrophy.
    Paoletti E
    Transplantation; 2018 Feb; 102(2S Suppl 1):S41-S43. PubMed ID: 28230637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus, the first mTOR inhibitor.
    Sánchez-Plumed JA; González Molina M; Alonso A; Arias M
    Nefrologia; 2006; 26 Suppl 2():21-32. PubMed ID: 17937632
    [No Abstract]   [Full Text] [Related]  

  • 10. Prophylactic use of mTOR inhibitors and other immunosuppressive agents in heart transplant patients.
    Santoni M; Massari F; Cascinu S
    Cell Mol Immunol; 2015 Jan; 12(1):122-4. PubMed ID: 24882385
    [No Abstract]   [Full Text] [Related]  

  • 11. mTOR Inhibition and Clinical Transplantation: Liver.
    Nashan B
    Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of mTOR inhibitors in adult solid organ transplantation.
    Ventura-Aguiar P; Campistol JM; Diekmann F
    Expert Opin Drug Saf; 2016; 15(3):303-19. PubMed ID: 26667069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mTOR inhibitors in pancreas transplant: adverse effects and drug-drug interactions.
    Fernandes-Silva G; Ivani de Paula M; Rangel ÉB
    Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):367-385. PubMed ID: 27659512
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 15. Treatment with mTOR inhibitors after liver transplantation enables a sustained increase in regulatory T-cells while preserving their suppressive capacity.
    Ghazal K; Stenard F; Dahlqvist G; Barjon C; Aoudjehane L; Scatton O; Conti F
    Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):237-244. PubMed ID: 29175009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of mTOR Inhibitors in the Management of Viral Infections: A Review of Current Literature.
    Bowman LJ; Brueckner AJ; Doligalski CT
    Transplantation; 2018 Feb; 102(2S Suppl 1):S50-S59. PubMed ID: 29369973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Everolimus and azoospermia, a causal relationship? About one case in a renal transplant patient].
    Wetzstein M; Weestel PF; Choukroun G
    Nephrol Ther; 2014 Feb; 10(1):44-5. PubMed ID: 24374233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive minimization with mTOR inhibitors and belatacept.
    Diekmann F
    Transpl Int; 2015 Aug; 28(8):921-7. PubMed ID: 25959589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Everolimus: a guide to its use in liver transplantation.
    Keating GM; Lyseng-Williamson KA
    BioDrugs; 2013 Aug; 27(4):407-11. PubMed ID: 23696253
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk?
    Bhat M; Watt KD
    Clin Transplant; 2015 Jul; 29(7):654-63. PubMed ID: 26094583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.